ERBB2 and breast cancer: Following initial improved disease-free survival in 2021 [77], increased overall survival was recently demonstrated on second interim analysis for HER-2 negative early BC (HR = 0.68; 98.5% CI = 0.47–0.97; p = 0.009) [78].